GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2012

VGXI to Manufacture GMP IL-12 Plasmid for OncoSec’s ElectroImmunotherapy Trials

  • OncoSec Medical inked an exclusive agreement with VGXI for the process development and large-scale cGMP production of interleukin-12 plasmid DNA (DNA IL-12) used in OncoSec’s ElectroImmunotherapy cancer treatment. OncoSec’s cancer therapy approach involves the use of electroporation, delivered using its OncoSec Medical System (OMS) device, to transiently increase the permeability of cancer cells to chemotherapy (OMS ElectroChemtherapy) or immunotherapeutics (ElectroImmunotherapy).

    The clinical-stage ElectroImmunotherapy product is an engineered DNA plasmid encoding IL-12. Three Phase II trials are ongoing in the treatment of metastatic melanoma, Merkel cell carcinoma, and cutaneous T-cell lymphoma.

    VGXI is a contract manufacturing organization specialized in the GMP production of DNA plasmids for use in human clinical trials. The firm offers a full spectrum of plasmid preparation services, from the manufacture of purified plasmid preparations for DNA vaccine and gene therapy research in small animals, through to preclinical plasmid production services for large animal testing, and cGMP production of injectable-grade plasmids for human clinical trials and commercial supply.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?